Nov 30, 2023 / 02:00PM GMT
Matthew Oliver O'Brien - Piper Sandler & Co., Research Division - MD & Senior Research Analyst
Joining us -- Matt O'Brien, I cover medtech here at Piper. We're very, very fortunate to have the Zimmer management team here with us this morning. From the company, we've got Ivan, who is CEO; Suky, who is the CFO; and then several members of the IR team as well. Thanks so much for coming out. Really do appreciate it. Great to be here.
Questions and Answers:
Matthew Oliver O'Brien - Piper Sandler & Co., Research Division - MD & Senior Research AnalystSo the question that comes up a lot that I'm sure you're prepared for and probably tired of answering is really the backlog that we're seeing and I know, Ivan, you're still pretty bullish as far as where we are in that process. How much longer can the backlog really be a tailwind for this sector? And then what do things look like when we start to kind of cycle out of backlog.
Ivan Tornos - Zimmer Biomet Holdings, Inc. - COO, President,
Trustpilot
